Frontiers in Genetics · Oct 27, 2026

Genetic variants in WDR4 influencing m7G modification are associated with prostate cancer susceptibility

By Jiang H, Diao S, Zhao J et al.

Introduction: The associations between genetic variants in N7-methylguanosine (m7G)-related genes and prostate cancer susceptibility remain unclear. This study investigated the relationship between WDR4 genetic variants and prostate cancer risk and explored their potential regulatory relevance. Methods: A discovery cohort from the PLCO study and an independent validation cohort from the PRACTICAL consortium were analyzed using logistic regression models. Functional annotation, expression quantitative trait locus analysis, RNA secondary-structure prediction, gene-expression analysis, survival analysis, and single-cell transcriptomic analysis were performed to investigate the potential biological relevance of associated variants. Results: The rs8130270 variant in WDR4 was associated with prostate cancer susceptibility in the discovery cohort (OR = 0.89, 95% CI = 0.82–0.96, P(FDR) = 2.65 × 10–2) and was validated in the PRACTICAL cohort (OR = 0.98, 95% CI = 0.97–1.00, P = 4.16 × 10–2). The rs8130270 C allele was associated with lower WDR4 expression in prostate tissue. WDR4 expression was higher in prostate cancer tissues, and high WDR4 expression was associated with poorer overall survival (HR = 1.67, 95% CI = 1.06–2.64, P = 2.00 × 10–2). Single-cell analysis showed that WDR4 was expressed across multiple immune and tumor-associated cell populations. Discussion: These findings suggest that rs8130270 in WDR4 may contribute to prostate cancer susceptibility through effects on WDR4 expression and provide genetic evidence supporting a potential role of WDR4-related m7G regulation in prostate cancer.

doi.org/10.3389/fgene.2026.1867208Open accessPubMed 43005729Mechanisms

AgingResearch.News